Article
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood - 1 Jul 2003
Branford Susan, Rudzki Zbigniew, Walsh Sonya, Parkinson Ian, Grigg Andrew, Szer Jeff, Taylor Kerry, Herrmann Richard, Seymour John F, Arthur Chris, Joske David, Lynch Kevin, Hughes Tim
Abstract excerpt
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have detectable BCR-ABL kinase domain mutations. It is unclear whether patients who remain sensitive to imatinib also have a significant incidence of mutations. We evaluated 144 patients treated with imatinib for BCR-ABL kinase domain mutations by direct sequencing of 40 accelerated phase (AP), 64 late chronic phase (> or =...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.